Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03DMN
|
|||
| Former ID |
DNC012006
|
|||
| Drug Name |
AKUAMMIGINE
|
|||
| Synonyms |
akuammigine; 642-17-1; UNII-1E21YYE0UM; 1E21YYE0UM; CHEMBL122404; C21H24N2O3; AC1LOQX5; SCHEMBL563799; MolPort-039-052-713; CHEBI:141878; ZINC53174616; PDSP1_001665; BDBM50030622; 9078AF; AKOS032948886; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (3beta,19alpha,20alpha)-; 4H-Indolo(2,3-a)pyrano(3,4-g)quinolizine-1-carboxylic acid, 4a,5,7,8,13,13b,14,14a-octahydro-4-methyl-, methyl ester, (4S,4aS,13bR,14aS)-; methyl (3beta,19alpha,20alpha)-19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H24N2O3
|
|||
| Canonical SMILES |
CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45
|
|||
| InChI |
1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16-,19+/m0/s1
|
|||
| InChIKey |
GRTOGORTSDXSFK-BMYCAMMWSA-N
|
|||
| CAS Number |
CAS 642-17-1
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:141878
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Inhibitor | [1] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.